Abstract
We report on the submucosal injection of bevacizumab (Avastin) at a dose of 0.3 to 3.75 mg per side in a patient with hereditary hemorrhagic telangiectasia. Application of such low doses has not been described in the literature yet. Our case report shows the positive effect of low-dose bevacizumab on therapy-refractory epistaxis. No complications were caused by the bevacizumab treatment.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized / administration & dosage*
-
Bevacizumab
-
Epistaxis / diagnosis
-
Epistaxis / etiology*
-
Epistaxis / prevention & control*
-
Female
-
Humans
-
Middle Aged
-
Telangiectasia, Hereditary Hemorrhagic / complications*
-
Telangiectasia, Hereditary Hemorrhagic / diagnosis
-
Telangiectasia, Hereditary Hemorrhagic / drug therapy*
-
Treatment Outcome
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab